Dr. Ankur Bahl

MBBS, MD (Internal Medicine), DM (Medical Oncology)

Senior Director – Medical Oncology

15+ Years of Experience
Gurgaon

Dr. Ankur Bahl is a highly accomplished and progressive leader in Medical Oncology, recognized across India for his expertise in molecular precision medicine, targeted therapies, and immunotherapy. An alumnus of Maulana Azad Medical College, he completed his DM in Medical Oncology at AIIMS, New Delhi. He also completed specialized courses in Adverse Drug Reactions and Pharmacovigilance at the University of Oxford, UK. Dr. Bahl is widely respected for his innovative approach to complex solid tumors, relying on cutting-edge genetic mapping to create customized treatment plans. He is also the founder of prominent oncology educational networks that stream live tumor boards to enhance peer collaboration globally.

  • Precision Immunotherapy: Deploying advanced immune checkpoint inhibitors tailored to specific tumor markers.
  • Head & Neck Oncology: Nationally renowned expert in targeted therapies for advanced oral and pharyngeal cancers.
  • Solid Tumor Specialization: Advanced chemotherapy and targeted biological agents for Lung, Breast, and Gastrointestinal cancers.
  • Hemat-Oncology: Targeted management for Acute Myeloid Leukaemia (AML), high-grade Lymphomas, and Myeloma.
  • Molecular Tumor Boards: Leading multidisciplinary genomic assessments for recurrent or resistant malignancies.
  • Served as Director of Medical Oncology at Max Super Speciality Hospital, Saket, before joining FMRI Gurgaon.
  • Published the largest Indian real-world clinical dataset on the use of Cetuximab (targeted therapy) in head and neck cancers.
  • Successfully designed and implemented hundreds of low-toxicity, outpatient-based concurrent chemo-immunotherapy protocols.
  • Active member of elite global oncology associations, including the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO).
  • Awarded for academic excellence and outstanding clinical research contributions at various national oncology forums.